Literature DB >> 16278421

Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems.

Mei-Hwei Chang1, Tony Hsiu-Hsi Chen, Hsu-Mei Hsu, Tzee-Chung Wu, Man-Shan Kong, Der-Cherng Liang, Yen-Hsuan Ni, Chien-Jen Chen, Ding-Shinn Chen.   

Abstract

PURPOSE: In spite of the success of hepatitis B immunization, still a significant proportion of childhood hepatocellular carcinoma (HCC) failed to be prevented by the hepatitis B immunization program. This study is aimed to investigate the problems in the HCC prevention in children. EXPERIMENTAL
DESIGN: All HCC children ages 6 to 14 diagnosed between 1981 and 2000 in Taiwan were collected from two national childhood HCC registry systems. We analyzed the causes of HCC prevention failure and the risk ratio of HCC among hepatitis B carriers born before versus after the vaccination program.
RESULTS: The incidence of HCC per 100,000 children declined from 0.54 to 0.20 in those born before versus after the vaccination program (risk ratio, 0.36). Vaccine failure (33.3-51.4%) and failure to receive hepatitis B immunoglobulin at birth (42.4-57.5%) were the main causes of HCC prevention failure. Mother-to-child transmission of hepatitis B virus infection is an important risk factor of HCC development. This is evidenced by the very high hepatitis B surface antigen seropositive rate in our HCC children (97%) and their mothers (96%). Hepatitis B carrier children born after the vaccination program had a higher risk of developing HCC than those born before the program (risk ratio, 2.3-4.5).
CONCLUSIONS: Vaccine failure and failure to receive hepatitis B immunoglobulin are the main problems preventing eradication of HCC. Hepatitis B carrier children born after the immunization program have a higher risk of developing HCC than those born before.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16278421     DOI: 10.1158/1078-0432.CCR-05-1095

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  31 in total

1.  Metastatic pancreatic adenocarcinoma presenting as a large pelvic mass mimicking primary osteogenic sarcoma: a series of two patient cases.

Authors:  Nicholas P Webber; Sunil Sharma; Allie H Grossmann; Akram Shaaban; Kevin B Jones; Lester J Layfield; R Lor Randall
Journal:  J Clin Oncol       Date:  2010-08-16       Impact factor: 44.544

2.  The war on cancer: a report from the front lines.

Authors:  Gavin Melmed
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-10

Review 3.  HPV-vaccination against cervical carcinoma: will it really work?

Authors:  Gerd Gross
Journal:  Med Microbiol Immunol       Date:  2007-02-21       Impact factor: 3.402

Review 4.  Natural history of hepatitis B virus infection: pediatric perspective.

Authors:  Yen-Hsuan Ni
Journal:  J Gastroenterol       Date:  2010-09-02       Impact factor: 7.527

5.  Natural history and clinical management of chronic hepatitis B virus infection in children.

Authors:  Mei-Hwei Chang
Journal:  Hepatol Int       Date:  2008-03-06       Impact factor: 6.047

Review 6.  [Impact of prophylactic HPV vaccines on dermatology and venereology].

Authors:  G Gross
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

7.  Increased childhood liver cancer mortality and arsenic in drinking water in northern Chile.

Authors:  Jane Liaw; Guillermo Marshall; Yan Yuan; Catterina Ferreccio; Craig Steinmaus; Allan H Smith
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

8.  Hepatitis B and hepatocellular carcinoma.

Authors:  Adrian M Di Bisceglie
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

9.  Characteristics of hepatitis B infection in a sample of omani patients.

Authors:  Khalid Al-Naamani; Ali Al-Maqbali; Siham Al-Sinani
Journal:  Sultan Qaboos Univ Med J       Date:  2013-06-25

10.  Immune persistence after hepatitis B vaccination in infancy - Fact or fancy?

Authors:  Terence T Lao
Journal:  Hum Vaccin Immunother       Date:  2016-01-25       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.